Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
Confirmed Presenting Companies:
Speaker Profile
Ph.D., Manager, Product Development, Invivoscribe
Biography
Dr. Conner focuses on advancing standardized molecular workflows for hematologic malignancies, with an emphasis on technologies that improve pan-cancer sample preparation, analytical consistency, and downstream testing performance. His work spans the development and implementation of molecular assays, software, and automated workflows designed to support reproducible results across laboratory and research settings. His scientific background is rooted in cell and molecular biology, with research experience across apoptosis, assay development, data analysis, and translational applications. He has contributed to the development of objective molecular testing solutions for hemato-oncology and brings a multidisciplinary perspective to the challenges of standardizing complex workflows for sensitive applications such as DNA analysis and measurable residual disease (MRD).
Talk
Standardize the Sample. Accelerate the Trial
Advanced MRD assays cannot overcome inconsistent pre-analytics. Standardizing cfDNA and DNA preparation across global trial sites can reduce variability, improve data consistency, and remove a critical barrier to scale. Automated extraction, concentration, and quantification can help accelerate biomarker-driven studies and strengthen the infrastructure supporting precision oncology.
Clinical & Research Tools Showcase:
Invivoscribe, Inc.
Invivoscribe is a global precision diagnostics company advancing standardized molecular testing for hematologic malignancies. Our portfolio spans sample preparation, companion diagnostics, clonality, MRD, bioinformatics, and a global network of laboratories offering flow and molecular services to support clinicians and biopharmaceutical partners worldwide.
Speaker Profile
M.D., Managing director, Biociencias SURA, Sura Colombia
Biography
Carlos Andrés Agudelo is an infectious disease physician with an MSc in Epidemiology and an MPH, and a Senior Researcher recognized by Colombia’s Ministry of Science. He is a professor in the Infectious Diseases postgraduate program at Universidad Pontificia Bolivariana and has led infection prevention and control programs and Colombia’s MDR-TB program. At SURA Colombia, he has served as Chief Scientific Officer and Director of Care Models and, for the past two and a half years, as Managing Director of SURA’s R&D unit, leading its research and innovation agenda
Talk
SURA: An Integrated Platform for HealthTech Innovation
Biociencias SURA combines large-scale health data, advanced omics capabilities, and clinical research infrastructure to help HealthTech companies generate evidence, validate innovations, and recruit patients through high-quality research processes, with a competitive cost advantage
Clinical & Research Tools Showcase:
Sura Colombia
)*: Biociencias is SURA’s health R&D platform, combining access to large-scale health data and SURA’s 13.1 million health plan members with advanced omics, clinical research, and AI capabilities. We partner with innovators to validate technologies, generate clinical evidence, and accelerate the path from innovation to real-world healthcare impact
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
